Meeting
2013 ASCO Annual Meeting
Use of serum markers in prediction of survival in the trapeze factorial trial evaluating docetaxel with zoledronic acid, strontium-89, or both in castrate-refractory prostate cancer (CRPC) metastatic to bone.
Authors
Vivek K Wadhwa
Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, Birmingham, United Kingdom
Vivek K Wadhwa , Sarah Pirrie , Kai Sheng Wen , Darren Barton , Nicholas David James
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5057)
DOI
10.1200/jco.2013.31.15_suppl.5057
Abstract #
5057
Poster Bd #
37H
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Skeletal events unrelated to bone metastasis in men with castration-refractory prostate cancer.
First Author: Kazumi Kamoi
Poster
2022 ASCO Genitourinary Cancers Symposium
Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2021 ASCO Annual Meeting
Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
First Author: Eddy Shih-Hsin Yang
Poster
2019 Genitourinary Cancers Symposium
Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies.
First Author: Panagiotis J. Vlachostergios